Cidara is pursuing an infectious disease-focused development strategy intended to transform standards of care and save lives.

Pipeline

Rezafungin

  IND-Enabling
Phase 1
Phase 2
Phase 3

Rezafungin Treatment (IV)

Candidemia and Invasive Candidiasis

Phase 3 Initiated

80%

Rezafungin Prophylaxis (IV)

Candida, PCP and Aspergillus in alloBMT


78%

Rezafungin Subcutaneous

Fungal Infections


26%

Cloudbreak

Research
IND-Enabling
Phase 1
Phase 2

Antiviral Fc Conjugates (AVCs)

Viral Infections – Influenza

Research

26%

GET IMPORTANT NEWS AND UPDATES BY EMAIL